| |||
ClinTech Research is well positioned to benefit in a variety of ways from its branches in both USA and India. ClinTech Research can be a guide to the business environment and operations in both USA and India. For example preclinical development services offered to Indian clients as well as USA clients. This principle can also be extended to include other services in research, manufacturing and clinical development in India where Bioavailability (BA)/Bioequivalence (BE) studies are frequently carried out. ClinTech Research is also in a good position to help Indian clients with regulatory liaison (such as 505b2) in the USA. Our R&D Connect services covers entire drug development that includes:
| |||
Why Us?
Drug Discovery - Chemistry & Biology: assay development, screening (HTS), lead optimization chemistry, in vitro ADME and pharmacokinetic studies Preclinical Drug Development: pharmacology, safety pharmacology, regulatory toxicology and toxicokinetics, analytical and bioanalytical method development and analysis, ADME studies, GLP study development and compliance chemical development, scale up and GMP manufacture of active pharmaceutical ingredients (API), analytical methods, stability testing, formulation development and GMP drug product manufacture Clinical Development: Bio-availability (BA), Bio-equivalence (BE), Phase I, Phase II and Phase III clinical trials, we can assist you in identifying additional sites in India earning you savings in the range of 30% to 70%. R&D Partnership: ClinTech Research is interested in establishing R&D partnership and/or find suitable alliances including co-development, in-licensing arrangement etc. to develop a drug molecule from preclinical to early clinical development in India. Regulatory Consulting: ClinTech Research provides local representation in India and the USA to our clients who do not have their offices in the representative country. For more information on any of our Indo-US R&D Connect services, please fill out our Contact Us form or call us at +1 (732) 623-4193. | |||
![]() |
|||